EYPT is now on another breakout on the 2h chart similar to what occurred from mid-December to mid-January. On the indicators the MACD shows the K/D lines on a steep upward slope. For me, what set off my interest was a relative volume scan that produced this stock on the list. The relative volume this week and consequential accumulation triggered the...
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for...
Prices taking support on an upward trend line. Fibonacci and previous major resistance levels support a likely 4:1 trading opportunity.
Buy from 5,6-5,8 with a stop loss of 3,5 and a target of and possibly 47.
EYPT Breakout Stock Alert Update BREAKOUT STOCK ALERT UPDATE $EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock Status Alert: Deficient Initial Alert Price: $4.78 Price High: $13 % Gains/Losses: 171.97% (+161% More Than Expected) Potential Stop Loss: $12.35 #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
BREAKOUT STOCK ALERT UPDATE $EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock Status Alert: Deficient Initial Alert Price: $4.78 Price High: $6.23 % Gains/Losses: 30.33% (+19.33% More Than Expected) Potential Stop Loss: $5.92 EYPT hit $6.17 after retesting the $5.29 Levels as we predicted hitting its 52-Wk High. The stock looks like it may be falling back...
Looking for entry above $5.03, Stop signal 4.37, Target 1 $6.37 and target 2 $8.87
I’m sharing this as an impromptu for this upcoming weeks Earnings regarding what stock looks like pre-R/S, being this severely damaged. I look forward to seeing how management goes forward with addressing the company’s current financial state. Technicals : - Stock at bottom of wedge = Bullish, for bounce play, especially “good” on news. - Weekly RSI...
XABCD construct in place from 09 means this is due to start the next wave any time from now and Q1
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets. Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both...
it has very strong support at $0.69. and also 50 days EMA cross to 200 days EMA. "this is just an idea." "trade at your own risk."
EYPT: EyePoint Pharmaceuticals, Inc. 2020-03-02 07:00:10 EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®
EYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions. Technical's: weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since. Symmetrical Triangle/ Breakout setup has been known...
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA. SHORT INTEREST 5.18M...
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 -...
Eyepoint pharmaceuticals today was added to the Russell 2000 and 3000. The pharmaceutical company has alot to prove this quarter with regards to their loan with CRG, but a earnings beat would spark investor/ hedge fund investment which could give potential massive upside for EYPT and current investors. Why EYPT After EYPT diluted (one of EYPT's pain points) more...